Saturday 17 October 2026
Export ARAV’s income statement to Excel — free account
ARAVIVE, INC
ARAV Healthcare Biotechnology
ARAVIVE, INC’s revenue for fiscal 2022 (year ended December 2022) was $9.1 million. Revenue growth for five consecutive years.
Follow ARAV
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | Trend | 2023e | 2024e | 2025e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | — | — |
Analyst estimates 2023–2025 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | — | — | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | 59 | 28 | 14 | 17 | 17 | 23 | 23 | ||||
| Revenue/emp, $m | — | — | — | 0.00 | 1.43 | 0.10 | 0.28 | 0.33 | 0.32 | 0.40 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | 40 | 1 | 5 | 6 | 7 | 9 | ||||
| Gross margin, % | — | — | — | 0.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |||||
| EBT | — | — | — | (96) | (85) | (76) | (18) | (31) | (39) | (76) | |||||
| EBT margin, % | — | — | — | 0.00 | (213.07) | (5,567.69) | (383.29) | (537.26) | (526.08) | (835.31) | |||||
| Net income | — | — | — | (96) | (85) | (76) | (18) | (31) | (39) | (76) | |||||
| Depreciation | — | — | — | 0 | 0 | 1 | 0 | 2 | 1 | 1 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 6.81 | 0.19 | 0.41 | 0.36 | 0.37 | 0.25 | ||||
| Earnings | — | — | — | (18.66) | (14.46) | (10.64) | (1.57) | (1.93) | (1.95) | (2.10) | |||||
| Cash flow | — | — | — | (7.92) | (19.81) | (4.08) | (1.47) | (0.77) | (1.60) | (1.79) | |||||
| Capex | — | — | — | (0.02) | (0.73) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (7.94) | (20.54) | (4.08) | (1.47) | (0.77) | (1.60) | (1.79) | |||||
| Book value | — | — | — | 29.44 | 14.10 | 8.36 | 5.96 | 3.04 | 2.10 | 0.29 | |||||
| Shares, m | — | — | — | 5 | 6 | 7 | 12 | 16 | 20 | 36 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | 0.00 | 0.00 | 0.00 | 8.53 | 5.91 | 5.14 | |||||
| P/B | — | — | — | — | 0.98 | 0.42 | 2.29 | 1.85 | 1.04 | 4.40 | |||||
| EV/Sales | — | — | — | — | 0.00 | 0.00 | 0.00 | 3.55 | (1.22) | (0.29) | |||||
| EV/FCF | — | — | — | — | (0.04) | 0.73 | (4.83) | (2.24) | 0.25 | 0.04 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (41) | (116) | (29) | (17) | (12) | (32) | (65) | ||||
| Capex | — | — | — | 0 | (4) | 0 | — | — | — | 0 | |||||
| Free cash flow | — | — | — | (41) | (121) | (29) | (17) | (12) | (32) | (65) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 151 | 76 | 56 | 63 | 52 | 45 | 36 | ||||
| Total debt | — | — | — | — | 5 | 7 | 8 | 6 | 4 | 2 | |||||
| Net debt | — | — | — | (201) | (76) | (50) | (65) | (61) | (59) | (54) | |||||
| Shareholders’ equity | — | — | — | 151 | 83 | 60 | 69 | 48 | 42 | 11 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (49.02) | (56.78) | (93.52) | (24.04) | (40.77) | (57.79) | (117.47) | ||||
| ROIC | — | — | — | 0.00 | (750.23) | (458.62) | (347.61) | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | (58.50) | (72.69) | (106.98) | (28.25) | (52.16) | (86.74) | (288.67) | |||||
Negative figures in brackets.
Fiscal years to Dec 2022 · latest quarter Sep 2023
Charts ten years each
ARAVIVE, INC vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| APVO Aptevo Therapeutics Inc. | $3.1M | 0.0× | — (loss-making) | +28.62% (above 0%: growing) | n/m | +23.11% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GRI GRI Bio, Inc. | $3.1M | 0.0× | — (loss-making) | — | n/m | +54.33% (above 0%: growing) | 0.00% | 0.00% | Compare |
| REVB Revelation Biosciences, Inc. | $3.0M | — (loss-making) | — | — | n/m | −35.29% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ARAV ARAVIVE, INC | $3.0M | — (loss-making) | — (loss-making) | −44.39% (below 0%: shrinking) | n/m | +48.19% (above 0%: growing) | 100.00% | (323.44%) | |
| DCOY Decoy Therapeutics Inc | $2.9M | 0.0× | — (loss-making) | −84.61% (below 0%: shrinking) | n/m | −212.47% (below 0%: shrinking) | 100.00% | (1,055.98%) | Compare |
| MBIO Mustang Bio, Inc. | $2.9M | — (loss-making) | — | — | n/m | +27.78% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BCAB BioAtla, Inc. | $2.9M | — (loss-making) | — (loss-making) | +4,233.33% (above 0%: growing) | n/m | +97.03% (above 0%: growing) | 100.00% | 3.49% | Compare |
| ONCO Onconetix, Inc. | $2.9M | 0.0× | — (loss-making) | −83.94% (below 0%: shrinking) | n/m | −36.00% (below 0%: shrinking) | 25.15% | (15,969.59%) | Compare |
| VIVS VivoSim Labs, Inc. | $2.8M | — (loss-making) | — (loss-making) | −51.35% (below 0%: shrinking) | n/m | +17.87% (above 0%: growing) | 100.00% | (15,327.78%) | Compare |
| Median of peers | $2.9M | 0.0× | — | −51.35% | — | +20.49% | 12.58% | 0.00% |
ARAVIVE, INC (ARAV) key facts
- ARAVIVE, INC (ARAV) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- ARAVIVE, INC’s revenue for fiscal 2022 (year ended December 2022) was $9.1 million.
- Return on equity was −288.7% and debt-to-equity 0.00.
- Its Piotroski F-score is 3 out of 9 for fiscal 2022.
ARAVIVE, INC (ARAV) Latest News
No news at this impact. Lower the threshold for more.